TW200831673A - TTK as tumor marker and therapeutic target for lung cancer - Google Patents

TTK as tumor marker and therapeutic target for lung cancer Download PDF

Info

Publication number
TW200831673A
TW200831673A TW096147377A TW96147377A TW200831673A TW 200831673 A TW200831673 A TW 200831673A TW 096147377 A TW096147377 A TW 096147377A TW 96147377 A TW96147377 A TW 96147377A TW 200831673 A TW200831673 A TW 200831673A
Authority
TW
Taiwan
Prior art keywords
peptide
egfr
seq
ttk
amino acid
Prior art date
Application number
TW096147377A
Other languages
English (en)
Chinese (zh)
Inventor
Yusuke Nakamura
Yataro Daigo
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of TW200831673A publication Critical patent/TW200831673A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
TW096147377A 2006-12-13 2007-12-12 TTK as tumor marker and therapeutic target for lung cancer TW200831673A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87479106P 2006-12-13 2006-12-13

Publications (1)

Publication Number Publication Date
TW200831673A true TW200831673A (en) 2008-08-01

Family

ID=39332098

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096147377A TW200831673A (en) 2006-12-13 2007-12-12 TTK as tumor marker and therapeutic target for lung cancer

Country Status (5)

Country Link
US (1) US20100009920A1 (enExample)
EP (3) EP2468887A1 (enExample)
JP (1) JP2010512730A (enExample)
TW (1) TW200831673A (enExample)
WO (1) WO2008072777A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7847060B2 (en) * 2005-02-25 2010-12-07 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
ES2339524B1 (es) * 2008-08-28 2011-03-22 Proyecto De Biomedicina Cima, S.L. Nuevo biomarcador como diana terapeutica en cancer de pulmon.
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
WO2011130644A2 (en) * 2010-04-16 2011-10-20 Arqule, Inc. Phosphorylated nf45 biomarkers, antibodies and methods of using same
ES2541054T3 (es) * 2010-10-20 2015-07-15 Université De Bordeaux Firmas del resultado clínico en tumores estromales gastrointestinales y método de tratamiento de tumores estromales gastrointestinales
KR101232084B1 (ko) * 2011-10-31 2013-02-08 연세대학교 산학협력단 암 세포 바이오 마커를 동정하는 방법 및 상기 방법으로 동정한 nmd-무관 암 세포 바이오 마커
CN105228642A (zh) * 2013-02-22 2016-01-06 纽约市哥伦比亚大学理事会 通过抑制转录因子atf5来抑制肿瘤细胞的组合物和方法
US10316077B2 (en) 2017-02-20 2019-06-11 Sapience Therapeutics, Inc. Cell-penetrating ATF5 polypeptides and uses thereof
CN109423517B (zh) * 2017-08-28 2022-08-05 中国医学科学院肿瘤医院 外泌体在肿瘤诊断、治疗和预后评估中的用途
JP6971508B2 (ja) 2018-01-03 2021-11-24 サピエンス・セラピューティクス・インコーポレーテッド Atf5ペプチド多様体及びそれらの使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ES2294844T3 (es) 1998-06-25 2008-04-01 Green Peptide Co., Ltd. Peptidos antigenicos tumorales derivados de ciclofilina b.
US20020103360A1 (en) 1998-09-01 2002-08-01 Yang Pan Novel protein related to melanoma-inhibiting protein and uses thereof
US20030045491A1 (en) * 2001-02-23 2003-03-06 Christoph Reinhard TTK in diagnosis and as a therapeutic target in cancer
CN101732717A (zh) * 2001-02-21 2010-06-16 诺华疫苗和诊断公司 用于诊断和作为癌症治疗靶标的ttk
CA2467936C (en) 2001-11-21 2013-11-05 Mitsubishi Chemical Corporation Method of inhibiting gene expression
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
ATE513843T1 (de) 2002-09-25 2011-07-15 Univ Massachusetts Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
DE602004015064D1 (de) * 2003-01-06 2008-08-28 Wyeth Corp Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
WO2005044976A2 (en) 2003-06-20 2005-05-19 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
US20050136437A1 (en) 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
WO2005045037A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2006021817A2 (en) 2004-08-23 2006-03-02 Sylentis S.A.U. Treatment of eye disorders characterized by an elevated introacular pressure by sirnas
EP2395109A1 (en) * 2004-12-08 2011-12-14 Aventis Pharmaceuticals Inc. Method for measuring resistance or sensitivity to docetaxel
EP2295601A1 (en) * 2005-02-10 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
US7847060B2 (en) * 2005-02-25 2010-12-07 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
US8053183B2 (en) * 2005-07-27 2011-11-08 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
TW201008574A (en) * 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Also Published As

Publication number Publication date
US20100009920A1 (en) 2010-01-14
JP2010512730A (ja) 2010-04-30
EP2102360A2 (en) 2009-09-23
EP2468886A1 (en) 2012-06-27
EP2468887A1 (en) 2012-06-27
WO2008072777A2 (en) 2008-06-19
WO2008072777A3 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
TW200831673A (en) TTK as tumor marker and therapeutic target for lung cancer
JP5764822B2 (ja) がんの治療および診断の標的遺伝子としてのprmt1
CN101835894A (zh) Ebi3、dlx5、nptx1和cdkn3用作肺癌治疗和诊断的靶基因
TWI816712B (zh) 癌促進因子表現抑制劑的有效成分之篩選用試藥及其篩選方法、癌之預防或治療劑的有效成分之篩選用試藥及其篩選方法、癌促進因子表現抑制劑及癌之預防或治療劑
KR20150122786A (ko) 암 전이의 진단, 예후 및 치료를 위한 방법
TW200922626A (en) Cancer-related genes, CDCA5, EPHA7, STK31 and WDHD1
WO2010095364A1 (en) Jarid1b for target gene of cancer therapy and diagnosis
KR102338510B1 (ko) 항-her2 치료제에 대한 동반진단 마커 및 이의 용도
US20100184047A1 (en) Screening and therapeutic method for nsclc targeting the cdca8-aurkb complex
CN101855346A (zh) Pkib和naaladl2用作前列腺癌治疗和诊断的靶基因
JP6519927B2 (ja) 癌の診断、阻害剤のスクリーニングにおけるrhoaの使用
JP4851451B2 (ja) 乳癌関連遺伝子znfn3a1
JP6064231B2 (ja) がん治療および診断のための標的遺伝子としてのsuv39h2
WO2022171136A1 (en) Methods for modulating a src-1 condensate
US20110263679A1 (en) C12orf48 as a target gene for cancer therapy and diagnosis
KR20110067107A (ko) 종양 마커 및 암에 대한 치료적 표적으로서 tbc1d7
JP2010501162A (ja) 肺癌の治療標的及び予後指標としてのimp−1癌遺伝子
WO2012023290A1 (en) Rasef as tumor marker and therapeutic target for cancer
WO2009113295A1 (en) C2orf18 as target gene for cancer therapy and diagnosis
JP2009502113A (ja) 乳癌を治療するための組成物および方法
KR20230140678A (ko) Rbm15 억제제를 포함하는 유방암의 예방 또는 치료용 약제학적 조성물
WO2012023288A1 (en) Fam161a as a target gene for cancer therapy and diagnosis
JP2012501169A (ja) がん関連遺伝子lgn/gpsm2
JP2010500004A (ja) 前立腺癌関連遺伝子styk1
KR20210035643A (ko) Myo1d의 발현 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물